<h2 dir="ltr"><strong>Short Bowel Syndrome</strong></h2>
<p dir="ltr"><strong><a href="https://www.delveinsight.com/report-store/short-bowel-syndrome-market-insight">Short Bowel Syndrome</a></strong> is a complex disease that occurs due to the physical loss or loss of function of a portion of the small and/or large intestine, resulting in reduced absorption of nutrients, fluids, vitamins, and minerals.</p>
<h3 dir="ltr"><strong>Short Bowel Syndrome Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" role="presentation">Total Diagnosed Prevalent Cases of SBS</li>
<li dir="ltr" role="presentation">Gender-specific Diagnosed Prevalent Cases of SBS</li>
<li dir="ltr" role="presentation">Age-specific Diagnosed Prevalent Cases of SBS</li>
<li dir="ltr" role="presentation">Etiology-specific Diagnosed Prevalent Cases of SBS</li>
</ul>
<h2 dir="ltr"><strong>Short Bowel Syndrome Epidemiology</strong></h2>
<ul>
<li dir="ltr" role="presentation">Diagnosed prevalent cases of Short Bowel Syndrome in the United States were estimated at approximately 14.5K in 2025.</li>
<li dir="ltr" role="presentation">In the US, females accounted for nearly 68% of diagnosed prevalent cases, while males represented approximately 32% of cases.</li>
<li dir="ltr" role="presentation">Among etiology-specific cases, surgical complications accounted for the highest number of SBS cases, representing nearly 4,100 cases, followed by mesenteric infarction in the United States.</li>
<li dir="ltr" role="presentation">The one-year survival rate for both pediatric and adult SBS patients ranges between 70&ndash;90%, reflecting improvements in supportive care, nutritional management, and multidisciplinary treatment approaches.</li>
<li dir="ltr" role="presentation">Increasing awareness, advancements in diagnosis, and improved long-term management strategies are expected to contribute to better patient outcomes during the forecast period.</li>
</ul>
<h2 dir="ltr"><strong>Short Bowel Syndrome Market</strong></h2>
<ul>
<li dir="ltr" role="presentation">The Short Bowel Syndrome market in the 7MM is expected to grow at a CAGR of 5% during the forecast period from 2026 to 2036.</li>
<li dir="ltr" role="presentation">The market size in the 7MM was estimated at approximately USD 2.5 billion in 2025.</li>
<li dir="ltr" role="presentation">In 2025, nearly 80% of the total market share was accounted for by the United States.</li>
<li dir="ltr" role="presentation">Among all therapies in the 7MM, Parenteral Support held the highest market share in 2025.</li>
<li dir="ltr" role="presentation">Takeda&rsquo;s GATTEX/REVESTIVE remains the leading approved therapy in the SBS market and is currently the only GLP-2 analog approved for both adult and pediatric SBS patients.</li>
<li dir="ltr" role="presentation">The SBS market is expected to expand due to increasing prevalence of underlying gastrointestinal disorders, advancements in parenteral nutrition, and growing adoption of targeted biologic therapies.</li>
</ul>
<h3 dir="ltr"><strong>Short Bowel Syndrome Market Drivers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Rising prevalence of underlying gastrointestinal and surgical conditions is contributing to increased SBS cases.</li>
<li dir="ltr" role="presentation">Advancements in parenteral nutrition and supportive care are improving patient survival and quality of life.</li>
<li dir="ltr" role="presentation">Expansion of biologics and targeted therapies is expected to transform SBS treatment approaches.</li>
<li dir="ltr" role="presentation">Growing adoption of novel therapies and improved disease awareness are supporting market growth.</li>
</ul>
<h3 dir="ltr"><strong>Short Bowel Syndrome Market Barriers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Limited therapeutic options continue to create challenges in long-term SBS management.</li>
<li dir="ltr" role="presentation">Therapeutic gaps in pediatric SBS remain a significant unmet clinical need.</li>
<li dir="ltr" role="presentation">Dependence on long-term nutritional support negatively impacts patient quality of life and increases healthcare burden.</li>
<li dir="ltr" role="presentation">High treatment costs may limit accessibility to advanced therapies in certain healthcare settings.</li>
</ul>
<h3 dir="ltr"><strong>Emerging Short Bowel Syndrome Drugs</strong></h3>
<ul>
<li dir="ltr" role="presentation">Apraglutide</li>
<li dir="ltr" role="presentation">Sonefpeglutide (HM15912)</li>
<li dir="ltr" role="presentation">MYTESI (crofelemer)</li>
<li dir="ltr" role="presentation">And others</li>
</ul>
<h3 dir="ltr"><strong>Key Short Bowel Syndrome Companies</strong></h3>
<ul>
<li dir="ltr" role="presentation">Takeda (Shire Pharmaceuticals)</li>
<li dir="ltr" role="presentation">Ironwood Pharmaceuticals (VectivBio)</li>
<li dir="ltr" role="presentation">Zealand Pharma</li>
<li dir="ltr" role="presentation">Hanmi Pharmaceutical</li>
<li dir="ltr" role="presentation">Napo Therapeutics (family company of Jaguar Health)</li>
<li dir="ltr" role="presentation">And others</li>
</ul>

Short Bowel Syndrome Market

Short Bowel Syndrome Infographics

Short Bowel Syndrome, Short Bowel Syndrome Infographics, Short Bowel Syndrome Market, Short Bowel Syndrome Pipeline